В Я Мельниченко
National Medical and Surgical Center named after N.I. Pirogov · 104 works · 632 citations · h-index 8
Top works
- Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
- Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis
- Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician’s and patient’s perspectives
- High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis
- Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170
- KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).
- Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial
- Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies
- Reduced Intensity Conditioning Regimen of Autologous Hematopoietic Stem Cell Transplantation±Mitoxantrone Consolidation In Multiple Sclerosis
- 183Clinical and quality of life monitoring in multiple sclerosis patients undergoing high dose chemotherapy and autologous stem cell transplantation
- P1091: FEASIBILITY OF ASCT AFTER ANTI-PD-1 THERAPY FOR R/R CLASSICAL HODGKIN LYMPHOMA
- Cardiotoxicity of High-Dose Chemotherapy with Autologous Hematopoietic Stem Cells Transplantation in Patients with Malignant Lymphomas. what is Worse - Beam or Cbv?
- Using Digital Technologies for Monitoring Patient’s Well-being and Quality of Life
- Clinical and Quality of Life Outcomes in Patients with Multiple Sclerosis (MS) after High Dose Chemotherapy(HDCT)+Autologous Stem Cell Transplantation (ASCT).
- Diagnostic and Prognostic Value of Biochemical Markers of Infectious Complications of High-Dose Therapy with Autologous Hematopoietic Stem Cell Transplantation in Malignant Lymphoproliferative Diseases
- Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
- P1692: UNMET NEEDS IN PATIENTS WITH “LOW RISK” POLYCYTHEMIA VERA (PV): SYMPTOM BURDEN AND QUALITY OF LIFE
- Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma
- Ten-year experience of the Pirogov Center in the organization of oncological care in a multi-field hospital
- First Line BR in Chronic Lymphocytic Leukemia Patients: Interim Results of Russian Norma Trial